Inter-lobar Fissure Completion in Patients With Failed Bronchoscopic Lung Volume Reduction
Eligible age
40–75 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this protocol is to perform a pilot prospective controlled clinical trial to evaluate the potential role of lung fissure completion with pleural adhesiolysis strategy (experimental intervention) in severe emphysema/COPD patients with failed bronchoscopic lung volume reduction (BLVR) via the use of endobronchial valves (EBVs) therapy. In select patients, the lung fissure completion with adhesiolysis strategy will be performed by video-assisted thoracoscopic surgery (VATS) guided stapling along the lung fissures to reduce collateral ventilation with adhesions removal and determine whether this experimental strategy will improve outcomes after failed BLVR in patients with severe emphysema/COPD.
Sponsor: Beth Israel Deaconess Medical Center
You may qualify if…
- ✓ Age 40 to 75 years.
- ✓ Stable with less than 10mg prednisone (or equivalent) daily.
- ✓ Nonsmoking for 4 months prior to screening and willing to not smoke during the study duration.
- ✓ Current pneumococcus vaccination.
- ✓ Current influenza vaccination.
- ✓ Target lung volume reduction \<350ml after bronchoscopic lung volume reduction (BLVR).
- ✓ Persistent dyspnea defined as an mMRC score greater or equal to 2 after bronchoscopic lung volume reduction (BLVR).
- ✓ Endobronchial valves (EBV) are still in place.
You may not qualify if…
- ✕ Clinically significant (greater than 4 tablespoons per day) mucus production.
- ✕ Myocardial infarction within 6 months of screening.
- ✕ Decompensated heart failure.
- ✕ Three or more pneumonia episodes in last year.
- ✕ Three or more COPD exacerbation episodes in the last year.
- ✕ Prior lung transplant, LVRS, bullectomy, or lobectomy.
- ✕ Clinically significant bronchiectasis.
- ✕ Unable to safely discontinue anticoagulants or platelet activity inhibitors for 7 days.
Where it's recruiting
Boston
Source: ClinicalTrials.gov · NCT05257681 · last updated 2026-04-13